Further re Shareholder Loan

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 31 October 2025 in relation to a potential shareholder loan (the "Loan") from David Nugent, a significant shareholder in the Company, that heads of terms for the Loan have now been agreed between the parties.

Subject to the signing of definitive agreements it is proposed that the Loan will include the following key terms:

• An aggregate amount of £1 million which can be drawn down by the Company in two equal tranches of £500,000 with the first tranche to be available to be drawn from the time that definitive legal agreements are entered into.
• When drawn the Loan will be secured against a fixed and floating charge over all of the Company's assets including its intellectual property and patents, until repaid in full.
• The first £500,000 tranche will be provided to genedrive without any commitment fees, charges or interest whereas the second tranche, if drawn, would incur a one-off fixed charge of £50,000 which will be added to the total amount of the loan when repaid. The second tranche can be drawn post 20 February 2026.
• The Loan is for a maximum period of twelve months from the date that the Loan documentation is signed.

The entering into of the Loan will represent a related party transaction under AIM Rule 13.

Dr Gino Miele, CEO of genedrive plc, said: "With heads of terms now agreed with David we will look to rapidly progress documentation to provide the Company with the optionality of accessing this Loan. On behalf of the Board I would like to extend my thanks to David for his indicated support for the Company which would significantly improve the Company's working capital position."

Mr David Nugent, said: "I look forward to further constructive discussions with Gino and the Board and ultimately ensuring that the Company has the financial and other resources it needs to deliver for patients and shareholders."